<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887106</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG1205-CL-101</org_study_id>
    <nct_id>NCT01887106</nct_id>
  </id_info>
  <brief_title>First-in-Human Single and Multiple Dose of GLPG1205</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1205 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this First-in-Human study is to evaluate the safety and tolerability after
      single ascending oral doses of GLPG1205 given to healthy male subjects, compared to placebo.
      Also, the safety and tolerability of multiple ascending oral doses of GLPG1205 given to
      healthy male subjects daily for 14 days compared to placebo, will be evaluated.

      Furthermore, during the course of the study after single and multiple oral dose
      administrations, the amount of GLPG1205 present in the blood and urine (pharmacokinetics) as
      well as the receptor occupancy by GLPG1205 in blood samples (pharmacodynamics) will be
      characterized compared to placebo.

      Also, the potential of cytochrome P450 (CYP)3A4 induction after repeated dosing with GLPG1205
      will be explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability after single dose</measure>
    <time_frame>Between screening and 7-10 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of GLPG1205 in comparison with placebo after a single oral dose in healthy subjects in terms of adverse events, physical examinations, vital signs, ECG and lab assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability after multiple doses</measure>
    <time_frame>Between screening and 7-10 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of GLPG1205 in comparison with placebo after multiple oral doses daily for 14 days in healthy subjects in terms of adverse events, physical examinations, vital signs, ECG and lab assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amount of GLPG1205 in plasma and urine over time after a single oral dose</measure>
    <time_frame>Between Day 1 predose and 48 hours post dose</time_frame>
    <description>To characterize the amount of GLPG1205 in plasma and urine over time - pharmacokinetics (PK) - after a single oral dose in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of GLPG1205 in plasma and urine over time after multiple oral doses</measure>
    <time_frame>Between Day 1 predose and Day 16 (48 hours after the last dose)</time_frame>
    <description>To characterize the amount of GLPG1205 in plasma and urine over time - pharmacokinetics (PK) - after multiple oral doses in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 6-b-hydroxycortisol/cortisol in urine</measure>
    <time_frame>Twelve hours before dosing on Day 1 and Day 14</time_frame>
    <description>To assess the potential of CYP3A4 induction after repeated dosing with GLPG1205 by means of the ratio of 6-b-hydroxycortisol/cortisol in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor occupancy by GLPG1205 on blood cells after a single dose</measure>
    <time_frame>Day 1 predose up to 24 hours post dose</time_frame>
    <description>To characterize the pharmacodynamics (PD) of GLPG1205 by means of receptor occupancy by GLPG1205 on blood cells after a single oral dose in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor occupancy by GLPG1205 on blood cells after multiple doses</measure>
    <time_frame>Day 1 and Day 14, predose up to 24 hours post dose</time_frame>
    <description>To characterize the pharmacodynamics (PD) of GLPG1205 by means of receptor occupancy by GLPG1205 on blood cells after multiple oral doses in healthy subjects</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG1205 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of GLPG1205 suspension - ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG1205 multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of GLPG1205 suspension - ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of placebo suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG1205 single ascending doses, oral suspension</intervention_name>
    <description>Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg</description>
    <arm_group_label>GLPG1205 single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo single ascending doses, oral suspension</intervention_name>
    <description>Single dose, oral suspension matching placebo</description>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG1205, multiple ascending doses, oral suspension</intervention_name>
    <description>Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg</description>
    <arm_group_label>GLPG1205 multiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, multiple ascending doses, oral suspension</intervention_name>
    <description>Multiple doses, daily for 14 days, oral suspension matching placebo</description>
    <arm_group_label>Placebo multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, age 18-50 years

          -  BMI between 18-30 kg/m2

        Exclusion Criteria:

          -  Any condition that might interfere with the procedures or tests in this study

          -  Drug or alcohol abuse

          -  Smoking
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric Vanhoutte, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS LSS Clinical Pharmacology Unit Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2013</study_first_submitted>
  <study_first_submitted_qc>June 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <last_update_submitted>October 13, 2013</last_update_submitted>
  <last_update_submitted_qc>October 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

